Antimicrobials | CMAC

Antimicrobials

Fluoroquinolones efficacy in acute sinusitis, acute exacerbation of chronic bronchitis and uncomplicated urinary tract infections

In May 2016 the U.S. Food and Drug Administration (FDA) approved changes to the labels of fluoroquinolone drugs for systemic use and advised to restrict their prescribing for the treatment of acute sinusitis, uncomplicated urinary tract infections …

Medication errors associated with the use of cephalosporins

Objective. To discover the prevalence and types of medication errors associated with the use of cephalosporins through analysis of national spontaneous reporting database. Materials and Methods. We conducted a retrospective analysis of 2324 spontaneous reports concerning adverse drug reactions associated with the cephalosporins. All the reports were submitted to the Russian pharmacovigilance database between 01.01.2012 and 01.08.2014. Approved prescribing drug information, standards of medical care and practical guidelines for certain conditions were used to identify medication errors associated with specific products.

Evidence Based Review on Daptomycin Use in the Treatment of Gram(+) Infections

Daptomycin is the only clinically used member of a cyclic lipopeptides class of antibiotics. Daptomycin has rapid bactericidal activity against not only rapidly growing, but also against slow growing bacterial cells including those in biofilms. …

New Drug Formulations of Posaconazole: Brief Clinical Pharmacology Review

Posaconazole is a second generation triazole with a broad spectrum of activity, which first appeared on the market in 2005 in the form of a suspension for oral administration. Despite some progress made in the framework of clinical trials, the …

Penicillin/Beta-lactamase Inhibitor Combinations in the Treatment of Bacterial Respiratory Tract Infections in Children

Over the several decades, medical and pharmaceutical science has been trying to solve the problem of antimicrobial therapy inefficiency due to rapidly increasing antimicrobial resistance. One of the antimicrobial agents being capable to overcome the …

Responsible Use of Antibiotics in Food Animals

Antimicrobial use in food animal medicine has become an important political and scientific issue, especially in relation to the contribution that animal sourced antimicrobial resistance might play in human medicine, leading to calls at a political …

Potential of the Introduction of Tedizolid for the Treatment of Complicated Skin and Soft Tissue Infections in a Russian Multi-Field Hospital

Increase in prevalence of methicillin-resistant Staphylococcus aureus (MRSA) strains among the pathogens of complicated skin and soft tissue infections (cSSTIs) in hospitalised patients demands introduction of new treatment options with improved …

A Novel View on Common Antibiotics: How to Properly Use Pharmacodynamic Parameters

The efficacy of antibacterial therapy is determined by multiple factors, including pharmacokinetic (PK) parameters of the antimicrobial agent. The predictive value of PK parameters has been confirmed in a number of in vivo experiments and clinical …

Efficacy and Safety of Lactobacillus acidophilus LA-5 and Bifidobacterium lactis BB-12 Combination in Gastroenterology, Pediatrics and Allergology

Bifidobacterium lactis BB-12 and Lactobacillus acidophilus LA-5 are the well-known probiotic strains. This review presents data on efficacy of the administration of BB-12 and LA-5 strains in several GI tract disorders: treatment of diarrhea, …

Potential for the Use of Fosfomycin in the Topical Treatment of Periprosthetic Joint Infection

Objective. To assess a potential for the use of fosfomycin as a component of polymethyl methacrylate-based bone cement in the topical treatment of periprosthetic infection. Materials and Methods. The most common pathogens of periprosthetic joint infection isolated during the 2013–2014 were studied. Susceptibility of 358 S. aureus and 19 E. coli strains to vancomycin, fosfomycin, and gentamicin was determined. Antimicrobial activity duration for the control samples of the gentamicin-containing bone cement (DEPUY CMW 1 GENTAMICIN) and the experimental samples with addition (per 20 g of cement) of 1 g or 2 g of vancomycin (5% or 10%), 2 g or 4 g of fosfomycin (10% or 20%) was investigated.